X
    學術可視化工作室RC   登錄   提交文稿
學術英文編修

EXPERT OPINION ON THERAPEUTIC TARGETS

期刊標題檢索 EXPERT OPIN THE 最新評論: What kind of submission status have you all been through? Mine is stil... (2023-06-01)


期刊名稱:   ISSN:   主題領域:   影響因子範圍: -
索引:   類別:   開放訪問:   排序方式:

[EXPERT OPINION ON THERAPEUTIC TARGETS]您好,您是該頁面的第 25658 位訪客。

期刊簡介
期刊名稱EXPERT OPINION ON THERAPEUTIC TARGETS EXPERT OPINION ON THERAPEUTIC TARGETS
LetPub Score
7.4
50 ratings
Rate

Reputation
8.8

Influence
6.4

Speed
7.0

期刊簡稱EXPERT OPIN THER TAR
ISSN1472-8222
E-ISSN1744-7631
h-index78
CiteScore
CiteScoreSJRSNIPCiteScore Rank
8.901.4230.975
Subject fieldQuartilesRankPercentile
Category: Pharmacology, Toxicology and Pharmaceutics
Subcategory: Pharmacology
Q152 / 313
Category: Pharmacology, Toxicology and Pharmaceutics
Subcategory: Drug Discovery
Q129 / 157
Category: Pharmacology, Toxicology and Pharmaceutics
Subcategory: Clinical Biochemistry
Q123 / 117
Category: Pharmacology, Toxicology and Pharmaceutics
Subcategory: Molecular Medicine
Q143 / 178

自引率 (2023-2024)2.20%自引率趨勢
掲載範囲
The journal evaluates molecules, signalling pathways, receptors and other therapeutic targets and their potential as candidates for drug development. Articles in this journal focus on the molecular level and early preclinical studies. Articles should not include clinical information including specific drugs and clinical trials.

The Editors welcome:

Reviews covering novel disease targets at the molecular level and information on early preclinical studies and their implications for future drug development.
Articles should not include clinical information including specific drugs and clinical trials.
Original research papers reporting results of target selection and validation studies and basic mechanism of action studies for investigative and marketed drugs.
The audience consists of scientists, managers and decision makers in the pharmaceutical industry, academic researchers working in the field of molecular medicine and others closely involved in R&D.
官方網站http://www.tandfonline.com/loi/iett20#.V48c20z9cSQ
在線稿件提交https://mc.manuscriptcentral.com/eott
開放訪問No
出版商Taylor and Francis Ltd.
主題領域医学
出版國/地區ENGLAND
發行頻率月刊
創刊年2001
每年文章數93每年文章數趨勢
黃金OA百分比13.79%
Web of Science 四分位
2023-2024
WOS Quartile: Q1

CategoryEditionJIF QuartileJIF RankingJIF Percentage
PHARMACOLOGY & PHARMACYSCIEQ157/354
索引 (SCI or SCIE)Science Citation Index Expanded
鏈接到PubMed Central (PMC)https://www.ncbi.nlm.nih.gov/nlmcatalog?term=1472-8222%5BISSN%5D
平均審稿時間 *來自出版商的數據:
來自作者的數據: Sort of slow, 4-8 Week(s)
競爭力 *來自作者的數據: Ordinary
參考鏈接
相關期刊 【EXPERT OPINION ON THERAPEUTIC TARGETS】CiteScore趨勢
自引率趨勢 每年文章數趨勢
作者評論
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。
  • 同一學科的期刊
  • CiteScore趨勢
  • 自引率趨勢
  • 每年文章數趨勢
  •  
    學科內的可信期刊 影響因子
    PHARMACOLOGICAL REVIEWSH-index: 210

    CiteScore: 34.70
    DRUG RESISTANCE UPDATESH-index: 100

    CiteScore: 26.20
    ADVANCED DRUG DELIVERY REVIEWSH-index: 278

    CiteScore: 28.10
    TRENDS IN PHARMACOLOGICAL SCIENCESH-index: 201

    CiteScore: 23.90
    PHARMACOLOGY & THERAPEUTICSH-index: 180

    CiteScore: 23.00
    MEDICINAL RESEARCH REVIEWSH-index: 119

    CiteScore: 29.30
    PHARMACOLOGICAL RESEARCHH-index: 118

    CiteScore: 18.70
    ARCHIVES OF PHARMACAL RESEARCHH-index: 75

    CiteScore: 13.40
    BIOMEDICINE & PHARMACOTHERAPYH-index: 78

    CiteScore: 11.90
    BRITISH JOURNAL OF PHARMACOLOGYH-index: 190

    CiteScore: 15.40
    學科內最受檢索的期刊 頁面查看次數
    BIOMEDICINE & PHARMACOTHERAPY498579
    PHYTOMEDICINE343291
    LIFE SCIENCES288963
    PHARMACOLOGICAL RESEARCH243027
    International Journal of Pharmaceutics242636
    European Journal of Pharmacology204466
    BIOCHEMICAL PHARMACOLOGY202914
    JOURNAL OF NATURAL PRODUCTS196809
    BRITISH JOURNAL OF PHARMACOLOGY165359
    MOLECULAR PHARMACEUTICS162931
  •  

    EXPERT OPINION ON THERAPEUTIC TARGETS EXPERT OPINION ON THERAPEUTIC TARGETS
    明年預測:
    穩步上升 無變化 逐步下降  刷新
  •  

     
  •  

     


首頁    上一頁    1    下一頁    末頁  (頁
/1)
  [EXPERT OPINION ON THERAPEUTIC TARGETS] 的評論撰寫評論
作者: 大力欣然


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-06-01 09:02:11 評論於
What kind of submission status have you all been through? Mine is still in Awaiting Commissioning Editor Processing
(0) 讚! | 大力欣然

作者: 西域凡雁


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-04-04 08:05:44 評論於
Hello, may I ask how long it took to receive it after the repair?
(0) 讚! | 西域凡雁

作者: 墟散筠心


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-01-03 21:48:56 評論於
Review speed: 6.0 | Submission hit rate: 50.0
Emphasized research direction: Targeted nanoformulations
Experience sharing: The review process is really slow, maybe it's an issue with my paper, it took 4 months to receive minor revision comments
(0) 讚! | 墟散筠心

作者: 多罗易青


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-11-04 12:05:18 評論於
Do you need to pay for the layout fee?
(0) 讚! | 多罗易青

作者: 维尔娜菲茨杰拉德


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-30 18:03:07 評論於
Thank you to the editors and reviewers; revisions have been made diligently, but experiments require time; confirming the time needed
(0) 讚! | 维尔娜菲茨杰拉德

作者: 维尔娜菲茨杰拉德


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-30 15:26:54 評論於
Please write a letter to the editor requesting an extension
(0) 讚! | 维尔娜菲茨杰拉德

作者: Oswald Edie


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-26 17:25:20 評論於
How to write a letter requesting an extension?
(0) 讚! | Oswald Edie

作者: 深渊兴业


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-26 12:51:40 評論於
How to apply for an extension?
(0) 讚! | 深渊兴业

作者: 雅韵小仙女


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2020-08-10 23:57:20 評論於
Do you need to provide the original data?
(0) 讚! | 雅韵小仙女

作者: 雷尔夫卡米拉


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2019-08-12 23:39:03 評論於
The review process is slow, and every reminder for submission is perfunctory
(0) 讚! | 雷尔夫卡米拉

作者: 东风谷东方


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2019-03-28 23:54:21 評論於
Submission acceptance rate: 25.0 Experience sharing: It is indeed very difficult, which refreshed my understanding of the speed of rejection. I submitted an article, and I received the acceptance and rejection emails at the same time. The time difference was only 4 minutes
(0) 讚! | 东风谷东方

作者: 凌霄高洁


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2017-07-16 09:20:46 評論於
Hesitating, but staying at this critical point, pushing further up is not easy. With over 4 points, I can consider it satisfactory
(0) 讚! | 凌霄高洁

作者: 中原谷枫


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2016-04-15 16:04:10 評論於
Review Speed: 2.0 | Submission Acceptance Rate: 50.0
Experience Sharing: It was extremely lucky that my article got accepted by this journal on the first try. The submission process and the journal's focus perfectly matched my research. After one round of revisions requiring the addition of siRNA to increase the persuasiveness of the article, the timeline was quite tight. I had to request an extension of the revision deadline. The editors were very nice, and once the article was accepted, it was published quickly. If time is not pressing, consider the Standard mode which doesn't require page fees. It's very cost-effective!
(0) 讚! | 中原谷枫

作者: 仙灵涒滩


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2015-05-13 19:42:52 評論於
I published an article 12 years ago, and now I am submitting another review article. I hope for good luck
(0) 讚! | 仙灵涒滩

作者: 凌霄高洁


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2013-04-03 09:48:57 評論於
Hoping for IF>4 in 2012. I recently published an article in this journal, focusing primarily on some new effects of drugs in clinical trials. It was quite challenging. The publication cycle for my article is approximately 5 months
(0) 讚! | 凌霄高洁

首頁    上一頁    1    下一頁    末頁  (頁
/1)

開始撰寫 [EXPERT OPINION ON THERAPEUTIC TARGETS] 的評論:





Contact us

Contact us  

Your name*

Your email*

Your message*

Please fill in all fields and provide a valid email.

Security Code*